That's right Craikey and it was only for a single preclinical asset targeting a single indication.
Remember Neuren's strategy: multiple therapeutic targets supported by the same investments, multiple potential outcomes at various stages, multiple paths to success. That's what get's me excited.
shire to gain ultra-orphan drug, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.54 |
Change
-0.490(2.88%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $16.94 | $17.02 | $16.38 | $10.33M | 620.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5061 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.62 | 1284 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |